Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/09/2021 09/10/2021 09/13/2021 09/14/2021 09/15/2021 Date
63.58(c) 63.13(c) 62.84(c) 62.11(c) 62(c) Last
11 245 981 10 017 217 9 031 468 8 009 689 7 981 363 Volume
-2.06% -0.71% -0.46% -1.16% -0.18% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 46 345 M - -
Net income 2021 6 495 M - -
Net Debt 2021 27 971 M - -
P/E ratio 2021 21,5x
Yield 2021 3,17%
Sales 2022 48 305 M - -
Net income 2022 8 023 M - -
Net Debt 2022 16 881 M - -
P/E ratio 2022 16,6x
Yield 2022 3,32%
Capitalization 138 B 138 B -
EV / Sales 2021 3,58x
EV / Sales 2022 3,20x
Nbr of Employees 30 250
Free-Float 76,0%
More Financials
Company
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are... 
Sector
Pharmaceuticals
Calendar
09/16 | 02:30amPresentation
More about the company
Ratings of Bristol-Myers Squibb Company
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about BRISTOL-MYERS SQUIBB COMPANY
07:00aBRISTOL MYERS SQUIBB : Five-Year Data from CheckMate -214 Show Opdivo (nivolumab..
BU
04:50aEXELIXIS : Says New Exploratory Data from Late-Stage Trial Show Potential of Kid..
MT
09/13BRISTOL MYERS SQUIBB : Says Phase 3 Trial of Opdivo Combined With Yervoy for Org..
MT
09/13BRISTOL MYERS SQUIBB : According to New Multinational Survey, Healthcare Provide..
BU
09/13BRISTOL MYERS SQUIBB : Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates ..
BU
09/13Bristol-Myers Squibb Company Announces Three-Year Data from the Checkmate -74..
CI
09/13TreeFrog Therapeutics announced that it has received €64 million in funding f..
CI
09/10BRISTOL MYERS SQUIBB : Shares Research Supporting Correlation Between New York H..
BU
09/09BRISTOL MYERS SQUIBB : Maintains Cash Dividend at $0.49 per common share, payabl..
MT
09/09BRISTOL MYERS SQUIBB : Announces Dividend
BU
09/09Bristol Myers Squibb Announces Quarterly Dividend, Payable on November 1, 202..
CI
09/08BOLT BIOTHERAPEUTICS : Bristol Myers Squibb to Study Combo Therapy for HER2-Expr..
MT
09/08BRISTOL MYERS SQUIBB : Bolt Biotherapeutics Announces Clinical Collaboration wit..
AQ
09/08Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squi..
CI
09/08BRISTOL MYERS SQUIBB : to Report Results for Third Quarter 2021 on October 27, 2..
BU
More news
News in other languages on BRISTOL-MYERS SQUIBB COMPANY
04:50aExelixis déclare que de nouvelles données exploratoires issues d'un essai de ..
09/09Bristol Myers Squibb annonce le versement d'un dividende trimestriel, payable..
09/07Pharma-Industrie geht von ausreichend Corona-Impfstoff für alle aus
09/03Sandoz Canada, filiale de Novartis, lance une version générique du médicament..
09/02Evotec erhält weitere Meilensteinzahlung von Bristol-Myers Squibb
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPANY
More recommendations
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | BMY | US1101221083 | MarketScreener
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 62,00 $
Average target price 75,89 $
Spread / Average Target 22,4%
EPS Revisions
Managers and Directors
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Executive VP
Rupert J. Vessey Executive VP-Research & Early Development
Joseph E. Eid Senior VP & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BRISTOL-MYERS SQUIBB COMPANY-0.05%137 771
JOHNSON & JOHNSON5.11%435 465
ROCHE HOLDING AG11.23%327 497
PFIZER, INC.21.46%251 011
NOVO NORDISK A/S49.16%231 607
ELI LILLY AND COMPANY38.43%211 895